13D Filing: Opko Health, Inc. and Vbi Vaccines Inc. (NASDAQ:VBIV)

---

CUSIP No. 91822J103		Schedule 13D		PAGE 4 of 5

Immediately following the Private Placement, the Issuer had 35,966,581 total issued and outstanding Common Shares. Therefore,
as a result of the Private Placement, OPKOs beneficial ownership in the Issuer increased to 5,990,603 shares of issued and outstanding Common Shares, or approximately 16.7%.

On December 7, 2016, OPKO acquired an additional 32,411 shares of Common Shares of the Issuer as a result of an adjustment to the anti-dilution clause in
connection with the Merger, and OPKOs beneficial ownership in the Issuer increased to 6,023,014 shares of issued and outstanding Common Shares, or approximately 15.1%.

The working capital of OPKO was the source of the funds for the purchase of all the Common Shares of the Issuer discussed above. No part of the purchase price
paid by OPKO was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the Common Shares described above.

ITEM 4.

Purpose of Transaction.

The Common Shares were all acquired by OPKO for investment purposes.

OPKO does not have any plans or proposals that relate to or that will result in any of the actions specified in clauses (a) through (j) of
Item 4 of Schedule 13D.

ITEM 5.

Interest in Securities of the Issuer.

(a)

OPKO is the direct owner of 6,023,014 Common Shares or 15.0% of the Issuers issued and outstanding Common Shares as of March 13, 2017, based on the Issuers Form 10-K as filed on March 20, 2017.

(b)

OPKO has the sole power to vote and dispose of the 6,023,014 Common Shares owned by it.

(c)

OPKO has not effected any transaction of the Common Shares during the last 60 days.

(d)

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by OPKO.

(e)

Not applicable.

ITEM 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Except for the transactions described in this Schedule 13D, OPKO does not have any contract, arrangement, understanding or relationship (legal or otherwise)
with any other person with respect to any securities of the Issuer, including but not limited to transfer or voting of any such securities, finders fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits,
division of profits or loss or the giving or withholding of proxies.

ITEM 7.

Material to be Filed as Exhibits.

None.